{"schema_version":"secwatch.filing_event.v1","accession":"0001872789-23-000029","form_type":"8-K","ticker":"EMBC","cik":"0001872789","company_name":"Embecta Corp.","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.225808+00:00","generated_at":"2026-06-07T22:54:01.062515+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Embecta Q4 revenue $281.9M (+2.7%); guides FY2024 revenue down 1-3%","bullets":["Q4 GAAP EPS $0.10, adjusted EPS $0.59; full-year adjusted EPS $2.99.","FY2024 revenue guidance $1,085-1,105M (reported -3% to -1%); adj. EPS $1.90-$2.10.","Dividend declared $0.15/share, payable Dec 15, 2023, record Dec 4.","Added as exclusive/dual-preferred brand with three top Medicare Part D payers starting Jan 2024.","Type 2 closed loop insulin pump development on track with FDA Breakthrough Device Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001872789-23-000029","json":"https://secwatch.observer/filing/0001872789-23-000029.json","markdown":"https://secwatch.observer/filing/0001872789-23-000029.md","text":"https://secwatch.observer/filing/0001872789-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1872789/000187278923000029/0001872789-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1872789/000187278923000029/embc-20231121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:54:01.062515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67d2eb861e321ae39dd5cae87c184fcd0f911779","claim":"Embecta Corp. updated its the quarter and fiscal year ended September 30, 2023 guidance (initiated).","evidence_excerpt":"Embecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1872789/000187278923000029/0001872789-23-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and fiscal year ended September 30, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}